首页 > 市场调查报告书 > 製药

呼吸器

特发性肺纤维化市场规模、份额和成长分析（按药物类型、作用机制、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1898584

特发性肺纤维化市场规模、份额和成长分析（按药物类型、作用机制、最终用户和地区划分）—2026-2033年产业预测

Idiopathic Pulmonary Fibrosis Market Size, Share, and Growth Analysis, By Drug Type (Nintedanib, Pirfenidone), By Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，特发性肺纤维化 (IPF) 市场规模将达到 43 亿美元，到 2025 年将达到 46 亿美元，到 2033 年将达到 78.9 亿美元，在预测期（2026-2033 年）内，复合年增长率为 6.98%。

特发性肺纤维化 (IPF) 发生率的不断上升，促使人们迫切需要有效的管理策略来改善患者的生活品质。不断增长的患者群体推动了对创新治疗方法的需求，并凸显了加强针对这种棘手疾病的医疗保健服务的必要性。关键的市场驱动因素包括有利的报销政策和对更优治疗方案日益增长的需求。人口老化、纤维化疾病的流行以及诊断技术的进步等因素进一步推动了市场成长。製药公司正积极投资于临床试验和创新治疗方法，以满足未被满足的医疗需求，从而显着扩展治疗选择。然而，现有治疗方案的限制可能会阻碍整体市场扩张，这凸显了开发 IPF 综合管理解决方案的迫切性。

全球特发性肺纤维化市场按药物类型、作用机制、最终用户和地区进行细分。依药物类型划分，可分为尼达尼布、Pirfenidone和其他药物类型。依作用机转划分，可分为抗纤维化药物、蛋白酪氨酸激酶抑制剂及其他作用机转。依最终用户划分，可分为医院/诊所、药房和其他最终用户。依地区划分，可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

特发性肺纤维化市场驱动因素

特发性肺纤维化市场受到该疾病发病率上升的显着影响，这主要是由于人口老化以及空气污染和职业风险因素等各种环境因素所造成的。此外，患者和医疗保健提供者对该疾病的认识不断提高，也导致该疾病的诊断频率增加。因此，对创新治疗和管理方案的需求日益增长，进一步推动了市场需求。盛行率的上升和对更有效治疗方法的寻求共同推动了特发性肺纤维化市场的扩张。

限制特发性肺纤维化市场的因素

特发性肺纤维化（IPF）市场面临的一大障碍是现有IPF药物价格过高。高昂的药费使许多患者无法坚持完成处方治疗，导致病情控制不佳，最终影响患者健康。这种经济负担不仅影响患者个体，也给医疗系统带来额外压力，尤其是在中低收入社区，这些地区获得基本治疗的机会仍然有限，造成了显着的医疗资源分配不均，进一步加剧了治疗这种致残性疾病的挑战，并阻碍了患者的整体治疗。

特发性肺纤维化（IPF）市场趋势

受遗传学进步和特定生物标记识别的推动，特发性肺纤维化 (IPF) 市场正呈现出向个人化医疗显着发展的趋势。这种向个人化治疗方案的转变使医疗专业人员能够根据每位患者的独特特征制定量身定制的治疗策略。这种方法不仅提高了治疗效果，改善了疾病管理，也有助于提升整体治疗效果。随着对个人化医疗解决方案的需求不断增长，IPF 市场预计将持续扩张，这反映了呼吸系统疾病和其他慢性疾病领域向精准医疗发展的更广泛趋势。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

United Therapeutics Corporation
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche Ltd
FibroGen Inc.
MediciNova Inc.
Jubilant Pharma Limited（Jubilant Cadista Limited）
Merck & Co. Inc.
Horizon Therapeutics Inc.
Avalyn Pharma Inc.
AstraZeneca
Novartis AG
GlaxoSmithKline plc
Genentech, Inc.
Biogen Inc.
Pfizer Inc.
AbbVie Inc.
Bayer AG
Amgen Inc.

简介目录

Product Code: SQMIG35H2223

Idiopathic Pulmonary Fibrosis Market size was valued at USD 4.3 Billion in 2024 and is poised to grow from USD 4.6 Billion in 2025 to USD 7.89 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026-2033).

The rising incidence of idiopathic pulmonary fibrosis (IPF) is intensifying the need for effective management strategies to improve patient quality of life. This growing demographic is fueling demand for innovative therapeutic approaches, highlighting the necessity for enhanced healthcare services tailored to this challenging condition. Key market drivers include favorable reimbursement policies and heightened demand for superior treatment options. Factors such as an aging population, the prevalence of fibrotic diseases, and advancements in diagnostic technologies are further propelling market growth. Pharmaceutical companies are actively investing in clinical trials and innovative therapies to address unmet medical needs, significantly broadening the treatment landscape. However, limited existing treatment options may hinder overall market expansion, underscoring the urgency for comprehensive solutions in IPF management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Idiopathic Pulmonary Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Idiopathic Pulmonary Fibrosis Market Segments Analysis

The global idiopathic pulmonary fibrosis market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Idiopathic Pulmonary Fibrosis Market

The idiopathic pulmonary fibrosis market is significantly influenced by the rising incidence of the condition, which is largely attributed to the aging population and various environmental factors, particularly air pollution and occupational hazards. Additionally, enhanced awareness among both patients and healthcare providers has led to more frequent diagnoses of this disease. As a result, there is a growing need for innovative treatment and management solutions, which drives further demand in the market. This combination of increased prevalence and the quest for better therapeutic options plays a crucial role in the expansion of the idiopathic pulmonary fibrosis market.

Restraints in the Idiopathic Pulmonary Fibrosis Market

A significant obstacle facing the idiopathic pulmonary fibrosis market is the exorbitant pricing of existing IPF medications. Many patients are dissuaded from adhering to their prescribed treatment regimens due to these high costs, leading to inadequate disease management and worsening health outcomes. This financial strain not only impacts individual patients but also places additional pressure on healthcare systems, particularly in low- and middle-income regions. In such areas, access to essential therapies remains limited and disproportionately uneven, further exacerbating the challenges associated with treating this debilitating condition and hindering overall patient care.

Market Trends of the Idiopathic Pulmonary Fibrosis Market

The idiopathic pulmonary fibrosis (IPF) market is witnessing a significant trend towards personalized medication, driven by advancements in genetics and the identification of specific biomarkers. This shift towards individualized treatment plans allows healthcare professionals to create tailor-made therapeutic strategies that cater to the unique characteristics of each patient. By enhancing the efficacy of therapies, this approach not only improves disease management but also elevates overall treatment outcomes. As the demand for personalized healthcare solutions rises, the IPF market is set to expand, reflecting a broader movement towards precision medicine in respiratory disorders and other chronic conditions.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pipeline Analysis
Patent Analysis

Idiopathic Pulmonary Fibrosis Market, By Drug Type

Market Overview
Nintedanib
Pirfenidone
Other Drug Types

Idiopathic Pulmonary Fibrosis Market, By Mode of Action

Market Overview
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Other Modes of Action

Idiopathic Pulmonary Fibrosis Market, By End User

Market Overview
Hospitals and Clinics
Pharmacies
Other End Users

Idiopathic Pulmonary Fibrosis Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

United Therapeutics Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FibroGen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediciNova Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharma Limited (Jubilant Cadista Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avalyn Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments